CR7622A - Secuencias del control del gen de corina humano - Google Patents

Secuencias del control del gen de corina humano

Info

Publication number
CR7622A
CR7622A CR7622A CR7622A CR7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A
Authority
CR
Costa Rica
Prior art keywords
corina
gene
control
sequences
human
Prior art date
Application number
CR7622A
Other languages
English (en)
Inventor
Pan Junliang
Wu Quingyu
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CR7622A publication Critical patent/CR7622A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

S e relaciona con el aislamiento , la clonacion, y la identificacion de las regiones de control de la expresion del gen de corina en mamiferos, incluyendo el promotor y otros elementos reguladores, y el uso de esta region de control de la expresion especifica del corazoon para indentificar nuevos agentes que modulan la expresion de gen de corina y para tratar enfermedades cardiacas.
CR7622A 2002-05-31 2004-12-15 Secuencias del control del gen de corina humano CR7622A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38410802P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
CR7622A true CR7622A (es) 2006-05-29

Family

ID=29711979

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7622A CR7622A (es) 2002-05-31 2004-12-15 Secuencias del control del gen de corina humano

Country Status (18)

Country Link
US (1) US20030223976A1 (es)
EP (1) EP1546172A4 (es)
JP (1) JP2005531302A (es)
KR (1) KR20050009724A (es)
CN (1) CN1671729A (es)
AU (1) AU2003245342A1 (es)
BR (1) BR0311603A (es)
CA (1) CA2487024A1 (es)
CR (1) CR7622A (es)
EC (1) ECSP045518A (es)
IL (1) IL165244A0 (es)
MX (1) MXPA04011944A (es)
NO (1) NO20045722L (es)
PL (1) PL374125A1 (es)
RS (1) RS104404A (es)
RU (1) RU2004139055A (es)
WO (1) WO2003102135A2 (es)
ZA (1) ZA200410400B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026255A1 (en) * 2002-06-25 2005-02-03 Morser John Michael Corin, a serine protease
WO2005084223A2 (en) * 2004-02-27 2005-09-15 The General Hospital Corporation Methods and compositions for hair growth
EP2172455B1 (en) 2005-12-01 2011-01-19 Basf Se Oxime ester photoinitiators
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
CN105734070A (zh) * 2016-04-11 2016-07-06 苏州大学 Corin基因变异体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917123A (en) * 1997-03-14 1999-06-29 University Of Pittsburgh Transgenic mice containing a nucleic acid encoding tumor necrosis factor-α under the control of a cardiac specific regulatory region
HUP0102811A3 (en) * 1998-06-05 2005-11-28 Schering Ag Corin, a serine protease
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
ATE496123T1 (de) * 2000-02-03 2011-02-15 Dendreon Corp Nukleinsäuren, welche für tramsmembran serin proteasen kodieren, die kodierten proteine und darauf basierende methoden
JP2001245671A (ja) * 2000-03-07 2001-09-11 Chiba Prefecture ヒト神経芽細胞腫においてクローニングされた新規遺伝子及び新規遺伝子の断片

Also Published As

Publication number Publication date
KR20050009724A (ko) 2005-01-25
PL374125A1 (en) 2005-10-03
WO2003102135A3 (en) 2004-11-04
BR0311603A (pt) 2005-06-07
EP1546172A2 (en) 2005-06-29
US20030223976A1 (en) 2003-12-04
MXPA04011944A (es) 2005-03-31
CA2487024A1 (en) 2003-12-11
AU2003245342A1 (en) 2003-12-19
ECSP045518A (es) 2005-03-10
EP1546172A4 (en) 2005-11-30
RS104404A (en) 2006-12-15
WO2003102135A2 (en) 2003-12-11
JP2005531302A (ja) 2005-10-20
IL165244A0 (en) 2005-12-18
ZA200410400B (en) 2006-06-28
NO20045722L (no) 2004-12-30
CN1671729A (zh) 2005-09-21
RU2004139055A (ru) 2005-08-20

Similar Documents

Publication Publication Date Title
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
PE20181922A1 (es) Terapia genica para tratar la hemofilia a
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
AR069393A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
CL2022001185A1 (es) Derivados terapéuticos de interleucina-22
CR7622A (es) Secuencias del control del gen de corina humano
ES2196313T3 (es) Utilizacion de inhibidores de la actividad del acido retinoico para el tratamiento de pieles sensibles y/o los daños agudos inducidos por las radiaciones uv.
DE60214207D1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
ATE552272T1 (de) Myostatin-isoform
ES2165233T3 (es) Empleo de 1-fosfato de esfingosina, derivados de 1-fosfato de esfingosina y/o sus mezclas para el tratamiento de enfermedades cutaneas inflamatorias.
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
AR039803A1 (es) Proteinas 1 y 2 relacionadas con el receptor ldl y tratamiento de los trastornos de huesos o cartilago
PT1276495E (pt) Utilizacao de tensioactivo pulmonar recombinante para o tratamento precoce de doencas pulmonares agudas
GT199900167A (es) Nuevos bis-benzimidazoles.
Tsoyi et al. Peptidylarginine Deiminase-2 Is Highly Expressed in Rheumatoid Arthritis-Associated Interstitial Lung Disease Derived Lung Fibroblasts and Contributes to Their Profibrotic Phenotype
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)